Key result
Myval THV improves device success over SEV, yielding ~81% less moderate-to-severe AR and lower PPI risk.
Why the study?
The comparative safety and efficacy of the Myval balloon-expandable valve versus self-expanding valves in patients undergoing TAVI remained an area of active investigation.
Does the Myval transcatheter heart valve improve device success and safety compared to self-expanding valves in patients undergoing TAVI?
Meta-Analysis (n=1,996)
Does the Myval transcatheter heart valve improve device success and safety compared to self-expanding valves in patients undergoing TAVI?
In a meta-analysis of 1,996 patients, the Myval balloon-expandable valve demonstrated superior periprocedural and 30-day device success with significantly lower rates of pacemaker implantation and paravalvular regurgitation compared to self-expanding valves.
Answers are grounded in this paper and cite their sources.
Supports Myval preference over SEV in TAVI; extends comparative evidence with superior device success and safety.
Background Transcatheter Aortic Valve Implantation(TAVI) is the preferred treatment for patients with severe aortic stenosis(AS) across various surgical risk categories.While self-expanding valves(SEV) are widely used due to their conformability and hemodynamic profile,the Myval transcatheter heart valve(THV),a newer-generation balloon-expandable valve(BEV),has been designed to improve annular sealing, reduce paravalvular aortic regurgitation(AR),and lower conduction disturbances. However, the comparative safety and efficacy of Myval versus SEV remain an area of active investigation. Purpose This study aimed to evaluate the comparative effectiveness and safety of Myval versus SEV in patients undergoing TAVI. Methods Our systematic review and meta-analysis was conducted according to the latest PRISMA guidelines. A comprehensive electronic literature search was performed across the three major databases—Cochrane, Medline, and Scopus—to identify relevant studies published up to December 19, 2024. The primary endpoint was device success assessed periprocedurally and at 30-days.Secondary endpoints included periprocedural,30-day and 1-year all-cause mortality,periprocedural device embolization,need for >1 THV,coronary arteries obstruction or occlusion and cardiac tamponade,30-day and 1-year stroke,30-day early safety,permanent pacemaker implantation(PPI),major and minor vascular complications,acute kidney injury(AKI),major bleeding and moderate or severe transvalvular AR. Results A systematic review and meta-analysis were performed, incorporating data from 5 studies involving 1,996 patients undergoing TAVI.Among them,790 patients received the Myval THV,while 1,206 were treated with SEV THVs.When compared to SEV, Myval was associated with a 5% higher rate of periprocedural (RR:1.05,95%CI:1.03–1.08,I²=0%) and an 8% higher rate of 30-day device success(RR:1.08,95%CI:1.03–1.13,I²=79%).Additionally,Myval exhibited a 16% improvement in 30-day early safety outcomes (RR:1.16,95%CI:1.04–1.28,I²=0%).Importantly,the risk of PPI was 40% lower in the Myval cohort compared to SEV (RR:0.60,95%CI:0.38–0.95,I²=44%),while Myval was associated with a 58% lower incidence of minor vascular complications (RR: 0.42, 95% CI: 0.18–0.98, I²=0%) and a 81% reduction in the risk of at least moderate transvalvular AR (RR:0.19,95%CI: 0.05–0.81,I²=76%), at 30-days.No statistically significant differences were observed between the two groups in the remaining clinical and procedural endpoints. Conclusion The Myval THV demonstrated superior periprocedural and 30-day device success, with significantly lower rates of PPI, minor vascular complications, and moderate or severe transvalvular AR, compared to the SEVs. Further randomized controlled trials with long-term follow-up are warranted to validate these findings.
No takes yet. Share an insight, caveat, or question.
Ktenopoulos et al. (2025) conducted a meta-analysis in Severe aortic stenosis (n=1,996). Myval transcatheter heart valve vs. Self-expanding valves (SEV) was evaluated on Device success assessed periprocedurally and at 30-days (RR 1.05, 95% CI 1.03-1.08). The Myval transcatheter heart valve demonstrated superior periprocedural and 30-day device success compared to self-expanding valves.
Synapse has enriched 10 related papers. Consider them for comparative context: